EP2709614A4 - Compositions pharmaceutiques et méthodes de traitement du cancer - Google Patents
Compositions pharmaceutiques et méthodes de traitement du cancerInfo
- Publication number
- EP2709614A4 EP2709614A4 EP12785724.1A EP12785724A EP2709614A4 EP 2709614 A4 EP2709614 A4 EP 2709614A4 EP 12785724 A EP12785724 A EP 12785724A EP 2709614 A4 EP2709614 A4 EP 2709614A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- pharmaceutical compositions
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161486851P | 2011-05-17 | 2011-05-17 | |
US201161538246P | 2011-09-23 | 2011-09-23 | |
PCT/US2012/038292 WO2012158884A1 (fr) | 2011-05-17 | 2012-05-17 | Compositions pharmaceutiques et méthodes de traitement du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2709614A1 EP2709614A1 (fr) | 2014-03-26 |
EP2709614A4 true EP2709614A4 (fr) | 2015-04-15 |
Family
ID=47177338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12785724.1A Withdrawn EP2709614A4 (fr) | 2011-05-17 | 2012-05-17 | Compositions pharmaceutiques et méthodes de traitement du cancer |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2709614A4 (fr) |
JP (1) | JP2014513730A (fr) |
AR (1) | AR086444A1 (fr) |
CA (1) | CA2836277A1 (fr) |
TW (1) | TW201309291A (fr) |
UY (1) | UY34078A (fr) |
WO (1) | WO2012158884A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57309B1 (sr) | 2010-02-16 | 2018-08-31 | Aragon Pharmaceuticals Inc | Modulatori androgenih receptora i njihove upotrebe |
BR112013002655A2 (pt) | 2010-08-04 | 2016-05-31 | Pellficure Pharmaceuticals Inc | novo tratamento de carcinoma de próstata |
AR083916A1 (es) * | 2010-11-18 | 2013-04-10 | Takeda Pharmaceutical | Metodo para tratar el cancer de mama y cancer de ovarios |
MX371020B (es) * | 2012-09-26 | 2020-01-13 | Aragon Pharmaceuticals Inc | Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico. |
JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
WO2014158875A1 (fr) * | 2013-03-14 | 2014-10-02 | Pellficure Pharmaceuticals Inc. | Nouvelle thérapie pour le carcinome de la prostate |
EP3280448B1 (fr) | 2015-04-10 | 2020-12-30 | Capsugel Belgium NV | Formulations lipidiques d'acétate d'abiratérone |
GB201510684D0 (en) * | 2015-06-17 | 2015-08-05 | Almac Diagnostics Ltd | Gene signatures predictive of metastatic disease |
TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
KR20200070334A (ko) | 2017-10-16 | 2020-06-17 | 아라곤 파마슈티컬스, 인코포레이티드 | 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090124587A1 (en) * | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US20100261689A1 (en) * | 2007-10-29 | 2010-10-14 | Masuo Yamaoka | Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264427A (en) * | 1992-01-29 | 1993-11-23 | Research Corporation Technologies, Inc. | 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors |
NZ596260A (en) * | 2006-03-29 | 2013-05-31 | Univ California | Diarylthiohydantoin compounds |
-
2012
- 2012-05-17 TW TW101117698A patent/TW201309291A/zh unknown
- 2012-05-17 EP EP12785724.1A patent/EP2709614A4/fr not_active Withdrawn
- 2012-05-17 CA CA2836277A patent/CA2836277A1/fr not_active Abandoned
- 2012-05-17 UY UY0001034078A patent/UY34078A/es not_active Application Discontinuation
- 2012-05-17 JP JP2014511521A patent/JP2014513730A/ja active Pending
- 2012-05-17 WO PCT/US2012/038292 patent/WO2012158884A1/fr active Application Filing
- 2012-05-18 AR ARP120101759A patent/AR086444A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090124587A1 (en) * | 2007-07-12 | 2009-05-14 | Auerbach Alan H | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS |
US20100261689A1 (en) * | 2007-10-29 | 2010-10-14 | Masuo Yamaoka | Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies |
Non-Patent Citations (1)
Title |
---|
See also references of WO2012158884A1 * |
Also Published As
Publication number | Publication date |
---|---|
TW201309291A (zh) | 2013-03-01 |
UY34078A (es) | 2012-11-30 |
AR086444A1 (es) | 2013-12-11 |
WO2012158884A1 (fr) | 2012-11-22 |
CA2836277A1 (fr) | 2012-11-22 |
JP2014513730A (ja) | 2014-06-05 |
EP2709614A1 (fr) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1209798A1 (en) | Compositions and methods for treating cancer | |
IL227429A0 (en) | The components and methods of cancer treatment | |
EP2755482A4 (fr) | Compositions et méthodes de traitement du cancer | |
EP2836482A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
EP2890720A4 (fr) | Compositions et méthodes de traitement du cancer | |
IL234989B (en) | Compounds and preparations containing them for the treatment of cancer | |
EP2771341A4 (fr) | Nouvelles compositions et procédés pour traiter le cancer | |
EP2688594A4 (fr) | Procédés et compositions pour le traitement du cancer | |
SG10201500124VA (en) | Methods and Compositions for Treating Cancer | |
EP2709614A4 (fr) | Compositions pharmaceutiques et méthodes de traitement du cancer | |
DK3292875T3 (en) | Compositions and methods for treating diseases | |
HK1202248A1 (en) | Compositions and methods for treating neurodegenerative disease | |
HK1202246A1 (en) | Compositions and methods for treating neurodegenerative disease | |
IL229231A0 (en) | Preparations and methods for the treatment of cancer | |
HK1216854A1 (zh) | 用於治療癌症的組合物和方法 | |
EP2823825A4 (fr) | Composition pharmaceutique pour traiter le cancer | |
EP2717865A4 (fr) | Méthodes et compositions pour le traitement du cancer du cerveau | |
SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
EP2863939A4 (fr) | Compositions et procédés pour le traitement du vitiligo | |
HK1188566A1 (zh) | 治療癌症的組合物和方法 | |
EP2928456A4 (fr) | Procédés et compositions pour le traitement du cancer | |
EP2582384A4 (fr) | Compositions et procédés de traitement du cancer | |
EP2537031A4 (fr) | Compositions et méthodes pour le traitement du cancer | |
HK1207561A1 (en) | Compositions and methods for treating hepatocellular cancer | |
PL2663318T3 (pl) | Kompozycja farmaceutyczna do leczenia raka |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150317 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20150311BHEP Ipc: A61K 31/4164 20060101ALI20150311BHEP Ipc: A61K 31/40 20060101AFI20150311BHEP Ipc: A61K 45/06 20060101ALI20150311BHEP Ipc: A61K 31/00 20060101ALI20150311BHEP Ipc: A61P 35/04 20060101ALI20150311BHEP Ipc: A61K 31/4188 20060101ALI20150311BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20151020 |